Status:

COMPLETED

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

Lead Sponsor:

Harold J. Burstein, MD, PhD

Collaborating Sponsors:

Celgene Corporation

Beth Israel Deaconess Medical Center

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abra...

Detailed Description

* Patients will receive regular chemotherapy every 2 weeks for up to 8 cycles (approximately 16 weeks total)of treatment. During the first four cycles patients will be treated with Adriamycin and Cyto...

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed breast cancer, with clinical stage I, II, or III disease
  • Must register at the beginning of adjuvant or neoadjuvant chemotherapy
  • 18 years of age or older
  • ECOG performance status of 0 or 1
  • Normal organ and marrow function

Exclusion

  • Previous cytotoxic chemotherapy or therapeutic radiation therapy for any reason
  • Pregnant or nursing
  • Receiving any other investigational agents
  • Patients with Stage IV breast cancer
  • Current grade II or greater peripheral neuropathy or prior history of grade II or greater neuropathy
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Immune deficiency when treated with marrow-suppressive therapy or HIV-positive patients receiving anti-retroviral therapy
  • Patients with sickle cell disease
  • Known history of hyperviscosity syndrome
  • Patients on lithium

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT00308178

Start Date

March 1 2006

End Date

June 1 2008

Last Update

February 18 2013

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Massacusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

3

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215